AEHR vs COHU: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
AEHR and COHU are similarly sized, but COHU trades noticeably cheaper on forward earnings (25.99x vs 57.82x): the market is paying up for AEHR's profile and pricing COHU more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.
AEHR vs COHU: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AEHR | COHU | What it tells you |
|---|---|---|---|
| Market cap | $2.61B | $2.26B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 57.82 | 25.99 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 3.18 | 1.55 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 58% of range | 53% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 11.83 | 2.93 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: COHU is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how AEHR and COHU affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AEHR and COHU share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AEHR and COHU exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Aehr Test Systems (AEHR) do?
Aehr Test Systems, headquartered in Fremont, California, designs and sells semiconductor test and burn-in equipment. Its FOX-P platform (FOX-XP and FOX-NP systems, plus WaferPak full-wafer contactors and DiePak carriers) performs wafer-level and singulated-die test, burn-in, and stabilization, processes that stress chips at elevated voltage and temperature to weed out early-life failures before the parts reach customers. Aehr also added ultra-high-power Sonoma systems for package-level burn-in of high-wattage devices. The company is one of the few suppliers offering both wafer-level and package-level burn-in across silicon carbide, gallium nitride, AI processors, silicon photonics, and flash memory.
What does Cohu (COHU) do?
Cohu, Inc. is a global supplier of test, automation, inspection, metrology, and software-analytics products and services to the semiconductor industry. Its equipment sits in the back end of chip manufacturing: test handlers (including thermal handlers like its Eclipse line), test contactors and interface products, inspection and metrology tools, and the software that runs and analyzes them. Roughly 40% of sales come from test and inspection systems, while about 60% is recurring revenue from interface products, spares, software, and services, which cushions the deep cyclicality of capital-equipment orders. Cohu serves customers across automotive, industrial, mobile, computing, and consumer chip end-markets, so its business tracks the broad health of the semiconductor cycle.
AEHR vs COHU: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- AEHR drivers: AI and data center diversification; Silicon photonics and optical interconnect.
- COHU drivers: AI and high-performance-computing ramp; Cyclical recovery in core end-markets.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Customer concentration is heavy: a small number of large semiconductor manufacturers drive most revenue, so the loss or delay of a single program can swing results materially. For COHU, cohu is small and cyclical, so its orders and revenue are lumpy and swing hard with the semiconductor capital-equipment cycle and with automotive, industrial, and computing chip demand it does not control.
AEHR or COHU: which should you pick?
AEHR vs COHU: the full fundamentals
AEHR. Aehr's results are choppy: Q3 FY2026 revenue fell about 44% year over year and the company posted a loss as silicon carbide softened, even while AI and data center bookings hit records. Because trailing earnings were negative, the P/E is not meaningful and the market cap reflects expectations for the AI pivot rather than current profits. All figures are approximate as of the dates noted and refresh each quarter; verify against Aehr's investor relations page or your broker.
COHU. As of June 2026 Cohu traded around a ~$2.8 billion market cap on roughly $481 million of trailing revenue, a price-to-sales ratio near 5.8x, while its trailing price-to-earnings ratio was negative because it was still posting losses coming out of the downturn. The valuation reflects an early-cycle recovery and AI/high-performance-computing optimism rather than current earnings, so results and the stock are sensitive to whether 2026 growth guidance of 20% to 25% and margin recovery actually materialize. Figures are approximate and change with each quarter and the chip cycle.
Headline figures (approximate, Q3 FY2026 (reported April 2026)): AEHR shows revenue (q3 fy2026) ~$10.3 million, down ~44% year over year from ~$18.3 million, revenue (fy2025, prior fiscal year) ~$59.9 million, gross margin (q3 fy2026) ~33% GAAP, ~37% non-GAAP, down on lower volume and mix, net income (q3 fy2026) GAAP net loss of ~$3.2 million, or ~$0.10 per share; COHU shows revenue (fy2025) ~$453 million (up ~13%), revenue (ttm) ~$481 million, q1 2026 revenue ~$125 million, net income (ttm) ~-$56 million (loss).
The bottom line: AEHR vs COHU
AEHR and COHU are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AEHR and COHU exposure against your real portfolio. It is not an investment adviser.
Wondering how AEHR or COHU fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Aehr Test Systems with AI
Connect the broker you already use and ask Walnut's AI how AEHR fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between AEHR and COHU?
+
Aehr Test Systems, headquartered in Fremont, California, designs and sells semiconductor test and burn-in equipment. Cohu, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AEHR or COHU the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AEHR or COHU?
+
On forward P/E (as of August 2026), AEHR trades at 57.82x and COHU at 25.99x, so COHU is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AEHR and COHU?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AEHR vs COHU?
+
AEHR: Customer concentration is heavy: a small number of large semiconductor manufacturers drive most revenue, so the loss or delay of a single program can swing results materially. The electric-vehicle and silicon carbide demand that powered prior years has softened, and management has stayed conservative about a SiC recovery. As a small-cap capital-equipment supplier, Aehr's orders are lumpy and tied to customers' capex cycles, which has already produced sharp year-over-year revenue declines and quarterly losses. The AI diversification is promising but still early and unproven at scale. COHU: Cohu is small and cyclical, so its orders and revenue are lumpy and swing hard with the semiconductor capital-equipment cycle and with automotive, industrial, and computing chip demand it does not control. It was still reporting trailing losses even as 2025 revenue grew, so the stock carries a negative trailing price-to-earnings ratio and depends on a recovery to reach sustained profitability. It competes against far larger, better-capitalized test-industry leaders like Teradyne and Advantest, and its high-performance-computing pipeline must convert from qualification to real production orders. Customer concentration, tariff and supply-chain costs, and geopolitical or export-control exposure in Asia add further risk, and the shares tend to be volatile.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AEHR or COHU; figures are approximate and dated (as of August 2026). Verify current data before investing.